CL2020002573A1 - Inhibidores atf6 y sus usos. - Google Patents

Inhibidores atf6 y sus usos.

Info

Publication number
CL2020002573A1
CL2020002573A1 CL2020002573A CL2020002573A CL2020002573A1 CL 2020002573 A1 CL2020002573 A1 CL 2020002573A1 CL 2020002573 A CL2020002573 A CL 2020002573A CL 2020002573 A CL2020002573 A CL 2020002573A CL 2020002573 A1 CL2020002573 A1 CL 2020002573A1
Authority
CL
Chile
Prior art keywords
atf6
inhibitors
compounds
diseases
treating
Prior art date
Application number
CL2020002573A
Other languages
English (en)
Inventor
Jennifer Alfaro
Sebastian Belmar
Vasquez Gonzalo Esteban Núñez
Brahmam Pujala
Sebastian Bernales
Sarvajit Chakravarty
Pooja Thakral
Rajesh Kumar Patidar
Balaji Dashrath Sathe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2020002573A1 publication Critical patent/CL2020002573A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan compuestos como inhibidores del factor de transcripción activador 6 (ATF6). Los compuestos pueden ser útiles como agentes terapéuticos para tratar enfermedades o trastornos mediados por ATF6 y pueden ser particularmente útiles para tratar infecciones virales, enfermedades neurodegenerativas, enfermedades vasculares o cáncer.
CL2020002573A 2018-04-06 2020-10-05 Inhibidores atf6 y sus usos. CL2020002573A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862654263P 2018-04-06 2018-04-06

Publications (1)

Publication Number Publication Date
CL2020002573A1 true CL2020002573A1 (es) 2021-03-05

Family

ID=66248737

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002573A CL2020002573A1 (es) 2018-04-06 2020-10-05 Inhibidores atf6 y sus usos.

Country Status (14)

Country Link
US (3) US10829485B2 (es)
EP (1) EP3774782A2 (es)
JP (2) JP7476167B2 (es)
KR (1) KR20210028144A (es)
CN (2) CN119060036A (es)
AU (1) AU2019247533B2 (es)
BR (1) BR112020020181A2 (es)
CA (1) CA3096139A1 (es)
CL (1) CL2020002573A1 (es)
IL (1) IL277794B2 (es)
MX (2) MX2020010469A (es)
RU (1) RU2020136310A (es)
SG (1) SG11202009570SA (es)
WO (1) WO2019195810A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195810A2 (en) 2018-04-06 2019-10-10 Praxis Biotech LLC Atf6 inhibitors and uses thereof
EP4041727A1 (en) * 2019-10-09 2022-08-17 Praxis Biotech LLC Atf6 modulators and uses thereof
US20230028584A1 (en) * 2019-10-09 2023-01-26 Praxis Biotech LLC Atf6 modulators and uses thereof
EP4001917A1 (en) * 2020-11-12 2022-05-25 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Inhibitors for use in treating liver disorders
KR102644194B1 (ko) * 2021-02-22 2024-03-08 주식회사 이노셀젠헬스케어 종양의 진단 및 치료를 위한 표적단백질로서의 atf6
US20240301417A1 (en) * 2021-06-16 2024-09-12 Sanford Burnham Prebys Medical Discovery Institute Methods and compositions for treating chronic liver disease and hepatocellular carcinoma
CN113501787A (zh) * 2021-08-20 2021-10-15 黑龙江省科学院石油化学研究院 一种合成6-三氟甲基-3-甲基吲唑的方法
TW202409023A (zh) 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
KR102820286B1 (ko) * 2022-08-31 2025-06-16 단국대학교 천안캠퍼스 산학협력단 퓨릴티아졸계 화합물 및 이를 유효성분으로 포함하는 근감소증 예방 또는 치료용 조성물
TW202434579A (zh) 2022-11-16 2024-09-01 瑞士商先正達農作物保護股份公司 殺微生物的四氫異喹啉衍生物
TW202439972A (zh) 2022-11-30 2024-10-16 瑞士商先正達農作物保護股份公司 殺真菌組成物
WO2024115512A1 (en) 2022-11-30 2024-06-06 Syngenta Crop Protection Ag Microbiocidal tetrahydroisoquinoline derivatives
PY2403614A (es) 2023-01-27 2025-09-11 Syngenta Crop Protection Ag Derivados de pirazol microbiocidas
AR131665A1 (es) 2023-02-01 2025-04-16 Syngenta Crop Protection Ag Composiciones fungicidas
AU2024325813A1 (en) * 2023-08-15 2026-03-05 Guangzhou Imd Pharmaceutical Co., Ltd. Compound targeting irak protein inhibition or degradation and use thereof
WO2025111184A1 (en) 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides
WO2025172368A1 (en) 2024-02-13 2025-08-21 Syngenta Crop Protection Ag (5-isoxazol-3-yl)-[4-(pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone derivatives for use as fungicides
CN119015423B (zh) * 2024-08-22 2025-09-02 中国兽医药品监察所 匹莫齐特作为非洲猪瘟病毒抑制剂的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50011B (sr) * 1998-04-20 2008-09-29 Pfizer Inc., Derivati piridin-3-karboksilne kiseline i njihova upotreba kao intermedijera
HUP0401292A3 (en) 2001-04-27 2011-01-28 Eisai R & D Man Co Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof
EP2385041B1 (en) * 2003-05-01 2013-09-18 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
CA2632021A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
AR069650A1 (es) * 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8901306B2 (en) * 2009-03-02 2014-12-02 Stemsynergy Therapeutics, Inc. Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell
US8385443B2 (en) 2009-07-17 2013-02-26 Qualcomm Incorporated Constructing very high throughput long training field sequences
KR101758046B1 (ko) 2009-12-22 2017-07-14 버텍스 파마슈티칼스 인코포레이티드 포스파티딜이노시톨 3-키나제의 이소인돌리논 억제제
JP5859778B2 (ja) 2011-09-01 2016-02-16 株式会社ニューフレアテクノロジー マルチ荷電粒子ビーム描画装置及びマルチ荷電粒子ビーム描画方法
RU2015106013A (ru) 2012-08-10 2016-10-10 Ф. Хоффманн-Ля Рош Аг Соединения пиразолкарбоксамида, композиции и способы применения
WO2014055944A1 (en) * 2012-10-04 2014-04-10 Oyagen, Inc. Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof
LT3286181T (lt) * 2015-04-22 2021-04-26 Rigel Pharmaceuticals, Inc. Pirazolo junginiai ir junginių gamybos bei naudojimo būdas
CA2990583A1 (en) 2015-06-22 2016-12-29 Sumitomo Dainippon Pharma Co., Ltd. 1,4-disubstituted imidazole derivative
CN114716381B (zh) 2015-12-16 2025-03-11 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
JP6896701B2 (ja) 2016-02-26 2021-06-30 大日本住友製薬株式会社 イミダゾリルアミド誘導体
US10357477B2 (en) 2016-09-13 2019-07-23 Regents Of The University Of Minnesota Anticancer compounds
US9911469B1 (en) * 2016-11-10 2018-03-06 Micron Technology, Inc. Apparatuses and methods for power efficient driver circuits
WO2019195810A2 (en) 2018-04-06 2019-10-10 Praxis Biotech LLC Atf6 inhibitors and uses thereof
JP2021522253A (ja) 2018-04-25 2021-08-30 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
US20230028584A1 (en) 2019-10-09 2023-01-26 Praxis Biotech LLC Atf6 modulators and uses thereof
EP4041727A1 (en) 2019-10-09 2022-08-17 Praxis Biotech LLC Atf6 modulators and uses thereof

Also Published As

Publication number Publication date
IL277794B1 (en) 2023-10-01
JP2021521271A (ja) 2021-08-26
US20240124434A1 (en) 2024-04-18
WO2019195810A2 (en) 2019-10-10
JP2024096924A (ja) 2024-07-17
RU2020136310A3 (es) 2022-05-06
SG11202009570SA (en) 2020-10-29
EP3774782A2 (en) 2021-02-17
KR20210028144A (ko) 2021-03-11
US20190367497A1 (en) 2019-12-05
CN112313224A (zh) 2021-02-02
JP7476167B2 (ja) 2024-04-30
IL277794B2 (en) 2024-02-01
AU2019247533B2 (en) 2023-09-28
IL277794A (en) 2020-11-30
US10829485B2 (en) 2020-11-10
CA3096139A1 (en) 2019-10-10
BR112020020181A2 (pt) 2021-01-19
MX2020010469A (es) 2021-04-19
CN112313224B (zh) 2024-08-13
US12325702B2 (en) 2025-06-10
AU2019247533A1 (en) 2020-10-15
MX2023010326A (es) 2023-09-14
US20210221803A1 (en) 2021-07-22
CN119060036A (zh) 2024-12-03
RU2020136310A (ru) 2022-05-06
WO2019195810A3 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
CL2020002573A1 (es) Inhibidores atf6 y sus usos.
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
MX2022009309A (es) Compuestos y usos de los mismos.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
MX389513B (es) Compuestos heterocíclicos como inmunomoduladores.
MX390535B (es) Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer.
MX389958B (es) 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
ECSP21026485A (es) Piridazinonas y sus métodos de uso
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX386471B (es) Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos
MX2017016681A (es) Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
GT201600250A (es) Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
MX2021002301A (es) Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
IL281244A (en) Combination therapy for the treatment of liver disease
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
MX2024013040A (es) Pirfenidona enriquecida con deuterio y metodos para su uso
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
MX378739B (es) Compuestos de 2-oxindol.
DK4225297T3 (da) Kombinationsbehandling til behandling af cancer
UY38352A (es) Inhibidores de integrina alfavbeta6